Prognostic value of aquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3785-3790

  Uramoto, Hidetaka ^a   Yamada, Tadaaki ^b   Yano, Seiji ^b   Kondo, Nobuyuki ^c   Hasegawa, Seiki ^c   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

EGFR; EMT; HGF; Lung adenocarcinoma; Mutation; Prognosis; Resistance; T790M

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GEFITINIB; K RAS PROTEIN; METHIONINE; PLAKOGLOBIN; THREONINE; UVOMORULIN; VIMENTIN; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CLINICAL ARTICLE; CODON; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPATHOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; EXON; FEMALE; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; JAPANESE; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PATIENT SELECTION; PLEURA EFFUSION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SKIN METASTASIS; TREATMENT RESPONSE; UPREGULATION; WILD TYPE; BIOSYNTHESIS; CANCER STAGING; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION; GENETICS; JAPAN; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84867021944     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, Sperduti I,Gelibter A, Scagliotti GV, Cognetti F and Giannarelli D: Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a metaanalysis. Ann Oncol 22: 2277-2285, 2011.
2. Uramoto H and Mitsudomi T: Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 96: 857-863, 2007. (Pubitemid 46452294)
3. Ma C, Wei S and Song Y: T790M and acquired resistance to EGFR TKI: A literature review of clinical reports. J Thorac Dis 3: 10-18, 2011.
4. Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Uramoto H, Yasumoto K, Kuwano M,and Ono M: Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring EGFR activating mutations. Cancer Res 70: 8715-8725, 2010.
5. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N,Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC and Jänne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007. (Pubitemid 46799492)
6. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005. (Pubitemid 40271173)
7. Uramoto H, Shimokawa H, Hanagiri T, Kuwano M and Ono M: Expression of selected genes for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer 73: 361-365, 2011.
8. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K and Noguchi M: Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6: 2011-2017, 2011.
9. Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 4: 1049-1059, 2009.
10. Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, Hanagiri T, Morita M and Yasumoto K: Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in nonsmall cell lung cancer in Japanese. Lung Cancer 51: 71-77, 2006. (Pubitemid 43088626)
11. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 68: 198-203, 2010.
12. Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K and Yasumoto K: Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, KRAS, MET, and hepatocyte growth factor status. J Thorac Oncol 5: 591-596, 2010.
13. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 30: 2513-2517, 2010.
14. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, Suehisa H, Ouchida M, Aoe K, Aoe M, Kiura K, Shimizu N and Date H: Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66: 7854-7858, 2006. (Pubitemid 44299146)
15. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J and Haber DA: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37: 1315-1316, 2005.
16. Uramoto H, Yano S and Tanaka F: T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI. Lung Cancer 76: 128-130, 2012.
17. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M and Miller VA: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17: 1616-1622, 2011.
18. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, Kris MG, Inoue A, Ladanyi M, Miller VA, Michor F and Pao W: Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3: 90ra59, 2011.
19. Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A, Bordoni A, Crippa S, Mazzucchelli L and Frattini M: Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 100: 1087-1094, 2009.
20. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH and Miller VA: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13: 5150-5155, 2007. (Pubitemid 47502083)
21. Pao W and Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760-774, 2010.
22. Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N and Nishio K: Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res 16: 4616-4624, 2010.
23. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M and Haber DA: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377, 2008.
24. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA and Jänne PA: Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88, 2010.
25. Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S and Hirata K: Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. Int J Cancer 129: 1410-1416, 2011.
26. Chikaishi Y, Uramoto H, and Tanaka F: The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma. Anticancer Res 31: 4451-4456, 2011.
27. Yoshino I, Kometani T, Shoji F, Osoegawa A, Ohba T, Kouso H, Takenaka T, Yohena T and Maehara Y: Induction of epithelial-mesenchymal transition-related genes by benzo[a]pyrene in lung cancer cells. Cancer 110: 369-374, 2007. (Pubitemid 47121898)
28. Gupta A, Srivastava S, Prasad R, Natu SM, Mittal B, Negi MP and Srivastava AN: Smoking intensity, oxidative stress and chemotherapy in non-small cell lung cancer: A correlated prognostic study. Biosci Trends 3: 191-199, 2009.